Exosomes bioengineered with VEGF siRNA targeted nucleolin-positive cancer cells (MDA-MA-231, leukemic cells), which enhanced the delivery of small RNAs to targeted tumor sites, leading to an anti-cancer effect [95]. Here, NUCLEOLIN is linked to neoplasm.